Clinical Trial Update: A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two dosing regimens of ABT-874 (briakinumab) to placebo in adults with moderate to severe chronic plaque psoriasis has completed, assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ABT-874 (briakinumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED